TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25930989

Group type: EXPERIMENTAL
Intervention: luseogliflozin
Number of subjects: 37

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 37
Study: 23389068

Group type: EXPERIMENTAL
Intervention: TAP block
Number of subjects: 68

Group type: COMPARATOR
Intervention: No TAP block (Control)
Number of subjects: 68
Study: 21829466

Group type: EXPERIMENTAL
Intervention: 30 µg GMZ2
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 100 µg GMZ2
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: GMZ2 (both doses)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Rabies vaccine
Number of subjects: 30
Study: 19687084

Group type: EXPERIMENTAL
Intervention: Irradiated polyglactin 910 absorbable sutures
Number of subjects: 59

Group type: COMPARATOR
Intervention: Non-absorbable sutures
Number of subjects: 59
Study: 17382134

Group type: EXPERIMENTAL
Intervention: Subinguinal microscopic varicocelectomy
Number of subjects: 120

Group type: COMPARATOR
Intervention: Open inguinal varicocelectomy
Number of subjects: 120

Group type: COMPARATOR
Intervention: Laparoscopic varicocelectomy
Number of subjects: 120
Study: 15017205

Group type: EXPERIMENTAL
Intervention: Diclofenac 100 mg suppository
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 11801926

Group type: EXPERIMENTAL
Intervention: 1:50,000 epinephrine
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 1:100,000 epinephrine
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 1:200,000 epinephrine
Number of subjects: 40

Group type: COMPARATOR
Intervention: 1% lidocaine (control)
Number of subjects: 40
Study: 9494422

Group type: EXPERIMENTAL
Intervention: Lobectomy with radical systematic lymph node dissection (dissection group, n = 59)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Lobectomy with lymph node sampling (sampling group, n = 56)
Number of subjects: 115
Study: 7919313

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control (non-steroid)
Number of subjects: 47
Study: 3210286

Group type: COMPARATOR
Intervention: Bland meal with 1950 mg of aspirin (positive control)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Spicy Mexican meal (30 g of jalapeño peppers)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Pepperoni pizza
Number of subjects: 12

Group type: COMPARATOR
Intervention: Bland meal of unpeppered steak and french fries (negative control)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Fresh jalapeño peppers placed directly into the stomach
Number of subjects: 12
Study: 868133

Group type: EXPERIMENTAL
Intervention: Isoniazid preventive treatment (300 mg daily for 24 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 31485864

Group type: EXPERIMENTAL
Intervention: Inoculated with 1 × 10^6 tachyzoites of the low virulence NC-Argentina LP1 isolate in sterile phosphate-buffered saline (PBS)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Mock inoculated with sterile PBS
Number of subjects: 48
Study: 27633397

Group type: EXPERIMENTAL
Intervention: SIT-WALK (sitting interrupted with 2min light-intensity walking bouts every 20min)
Number of subjects: 25

Group type: COMPARATOR
Intervention: SIT-STAND (sitting interrupted with 2min standing bouts every 20min)
Number of subjects: 25

Group type: COMPARATOR
Intervention: SIT-ONLY (uninterrupted sitting)
Number of subjects: 25
Study: 26382173

Group type: EXPERIMENTAL
Intervention: PTAS plus aggressive medical therapy
Number of subjects: 451

Group type: COMPARATOR
Intervention: Aggressive medical therapy alone
Number of subjects: 451
Study: 22449201

Group type: EXPERIMENTAL
Intervention: P‐3051 (8% ciclopirox)
Number of subjects: 0

Group type: COMPARATOR
Intervention: MRF (5% amorolfine)
Number of subjects: 0
Study: 22367664

Group type: EXPERIMENTAL
Intervention: Methylphenidate delivered through a long‐acting transdermal system (MTS) for 3 months
Number of subjects: 17

Group type: COMPARATOR
Intervention: No-medication condition for 3 months
Number of subjects: 17
Study: 19697299

Group type: EXPERIMENTAL
Intervention: Reminiscence therapy (8 sessions over 2 months)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Comparison group (no reminiscence therapy)
Number of subjects: 92
Study: 17408628

Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate (40 mg every second day)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Estradiol valerate (2 mg daily)
Number of subjects: 36
Study: 15823886

Group type: EXPERIMENTAL
Intervention: Co‐financed collaboration model
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional care
Number of subjects: 0
Study: 11970780

Group type: EXPERIMENTAL
Intervention: Outgroup members (black and white)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ingroup members (shaded)
Number of subjects: 0
Study: 9814478

Group type: EXPERIMENTAL
Intervention: Basal muscle sympathetic nerve activity (MSNA)
Number of subjects: 39
Study: 8106694

Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy (recombinant tissue‐type plasminogen activator, urokinase or combination therapy) with heparin, aspirin, and calcium‐channel blocking agent.
Number of subjects: 1001
Study: 2520637

Group type: EXPERIMENTAL
Intervention: Histamine-receptor blockade with 10 mg of chlorpheniramine and 400 mg of cimetidine intravenously before protamine infusion.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no histamine-receptor blockade).
Number of subjects: 0
Study: 335482

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate 400 microgram per day for four weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate
Number of subjects: 0
Study: 30488484

Group type: EXPERIMENTAL
Intervention: Empirical peer groups based on patient-sharing in claims data
Number of subjects: 142098

Group type: COMPARATOR
Intervention: Randomly assigned peer groups
Number of subjects: 142098

Group type: COMPARATOR
Intervention: Empirical peer groups compared to hospital groups
Number of subjects: 142098
Study: 28476096

Group type: EXPERIMENTAL
Intervention: Percutaneous Chevron/Akin (PECA)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Open Scarf/Akin (SA)
Number of subjects: 50
Study: 25161168

Group type: EXPERIMENTAL
Intervention: EMPOWER intervention (n = 29)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Healthy Lifestyles control (n = 28)
Number of subjects: 57
Study: 24368464

Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 130

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study: 22398344

Group type: EXPERIMENTAL
Intervention: 8-week Hatha yoga intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Light exercise group (control)
Number of subjects: 0
Study: 19381522

Group type: EXPERIMENTAL
Intervention: Inhaled milrinone administered via jet nebulizer for 4 hours
Number of subjects: 48

Group type: COMPARATOR
Intervention: Intravenous milrinone (50 microg/kg bolus, then 0.5 microg/kg/min infusion for 4 hours)
Number of subjects: 48
Study: 16847294

Group type: COMPARATOR
Intervention: Statins
Number of subjects: 1384
Study: 14722591

Group type: EXPERIMENTAL
Intervention: Virtual reality distraction intervention
Number of subjects: 20

Group type: COMPARATOR
Intervention: No distraction intervention (control condition)
Number of subjects: 20
Study: 10912546

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) therapy, 4 IU/m2 per day, for a maximum of 8 years
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) therapy
Number of subjects: 45
Study: 9065965

Group type: EXPERIMENTAL
Intervention: 2.5 mg lorazepam
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8351307

Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 3555046

Group type: EXPERIMENTAL
Intervention: Oral ciprofloxacin (750 mg twice daily)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Other antimicrobial therapy
Number of subjects: 30
Study: 29749371

Group type: EXPERIMENTAL
Intervention: Modafinil (100 mg twice a day)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Intranasal mometasone furoate (100 µg in the evening)
Number of subjects: 250
Study: 27549387

Group type: EXPERIMENTAL
Intervention: Propofol-remifentanil anesthesia with rocuronium 0.3 mg/kg
Number of subjects: 368

Group type: EXPERIMENTAL
Intervention: Propofol-remifentanil anesthesia with rocuronium 0.6 mg/kg
Number of subjects: 368

Group type: EXPERIMENTAL
Intervention: Propofol-remifentanil anesthesia with rocuronium 0.9 mg/kg
Number of subjects: 368

Group type: COMPARATOR
Intervention: Sevoflurane-remifentanil anesthesia with rocuronium 0.3 mg/kg
Number of subjects: 368

Group type: COMPARATOR
Intervention: Sevoflurane-remifentanil anesthesia with rocuronium 0.6 mg/kg
Number of subjects: 368

Group type: COMPARATOR
Intervention: Sevoflurane-remifentanil anesthesia with rocuronium 0.9 mg/kg
Number of subjects: 368

Group type: EXPERIMENTAL
Intervention: Propofol-remifentanil anesthesia
Number of subjects: 368

Group type: COMPARATOR
Intervention: Sevoflurane-remifentanil anesthesia
Number of subjects: 368
Study: 24252943

Group type: EXPERIMENTAL
Intervention: Prostaglandin E1
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Natriuretic peptide
Number of subjects: 60
Study: 22472338

Group type: EXPERIMENTAL
Intervention: Mannequin simulation of an adverse event
Number of subjects: 16

Group type: COMPARATOR
Intervention: Written description of an adverse event
Number of subjects: 16
Study: 19967631

Group type: EXPERIMENTAL
Intervention: Oolong tea (O)
Number of subjects: 982

Group type: COMPARATOR
Intervention: Barley tea (B)
Number of subjects: 982

Group type: COMPARATOR
Intervention: Distilled water (W)
Number of subjects: 982
Study: 17920718

Group type: EXPERIMENTAL
Intervention: Interferon-alpha treatment for 52 weeks
Number of subjects: 31
Study: 16110408

Group type: EXPERIMENTAL
Intervention: Docetaxel-based chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bisphosphonates
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Molecular targeted therapy (tyrosine kinase inhibitors, anti-sense oligonucleotides, angiogenesis inhibitors, endothelin receptor antagonists)
Number of subjects: 0
Study: 12409680

Group type: EXPERIMENTAL
Intervention: Venlafaxine (n=843)
Number of subjects: 2027

Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitors (SSRIs) (n=743)
Number of subjects: 2027

Group type: COMPARATOR
Intervention: Placebo (n=441)
Number of subjects: 2027

Group type: EXPERIMENTAL
Intervention: ADAM score
Number of subjects: 2027
Study: 10567778

Group type: EXPERIMENTAL
Intervention: gemifloxacin, 320 mg p.o. once daily
Number of subjects: 15

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 15
Study: 7589039

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 50

Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 50
Study: 2177482

Group type: EXPERIMENTAL
Intervention: Hypertonic sodium bicarbonate (HSB) 100 mEq IV over 5 minutes
Number of subjects: 10

Group type: COMPARATOR
Intervention: Normal saline IV over 5 minutes
Number of subjects: 10
Study: 44375

Group type: EXPERIMENTAL
Intervention: Sulpiride (400 ‐‐ 2100 mg/day)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 29940565

Group type: EXPERIMENTAL
Intervention: Extended first-trimester combined screening (eFTCS) with assessment of nasal bone, tricuspid flow, and ductus venosus flow.
Number of subjects: 688

Group type: COMPARATOR
Intervention: Ultrasound + cell-free DNA (cfDNA) screening.
Number of subjects: 688
Study: 28741675

Group type: EXPERIMENTAL
Intervention: Dinalbuphine sebacate (DNS) 150 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Nalbuphine HCl 20 mg
Number of subjects: 12
Study: 26395825

Group type: EXPERIMENTAL
Intervention: Yoga-based exercise (YE)
Number of subjects: 20
Study: 23721547

Group type: EXPERIMENTAL
Intervention: Arbaclofen placarbil (20 or 40 mg once daily, 20 or 30 mg twice daily)
Number of subjects: 460

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 460

Group type: EXPERIMENTAL
Intervention: Arbaclofen placarbil (all doses)
Number of subjects: 460
Study: 21495899

Group type: EXPERIMENTAL
Intervention: Omelette lunch
Number of subjects: 31

Group type: COMPARATOR
Intervention: Jacket potato lunch
Number of subjects: 31

Group type: COMPARATOR
Intervention: Chicken sandwich lunch
Number of subjects: 31
Study: 19654232

Group type: EXPERIMENTAL
Intervention: Dialysate calcium concentration (D(Ca)) of 1.00 mmol/L
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Dialysate calcium concentration (D(Ca)) of 1.50 mmol/L
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Dialysate calcium concentration (D(Ca)) of 1.25 mmol/L
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Higher D(Ca) levels
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Post-HD
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Increasing level of iCa
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: DeltaMBP
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Higher DeltaMBP and higher ultrafiltration
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Variation in heart rate and DeltaMBP
Number of subjects: 18
Study: 15677600

Group type: EXPERIMENTAL
Intervention: Buprenorphine (12-16 mg)
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Methadone (65-85 mg p.o.)
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Contingency management
Number of subjects: 162

Group type: COMPARATOR
Intervention: Performance feedback
Number of subjects: 162
Study: 12687829

Group type: EXPERIMENTAL
Intervention: Radiofrequency (RF) catheter ablation of AF
Number of subjects: 69
Study: 10592952

Group type: EXPERIMENTAL
Intervention: Syrup of ipecac (SI) + home observation (HO)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Home observation (HO) alone
Number of subjects: 103
Study: 8725983

Group type: EXPERIMENTAL
Intervention: Antibiotics for respiratory tract infections
Number of subjects: 3610
Study: 1807700

Group type: EXPERIMENTAL
Intervention: Individualized feedback from a clinical preceptor and study librarian on first 10 searches after a 1-hour training class and 1 hour of individualized searching.
Number of subjects: 308

Group type: COMPARATOR
Intervention: No further intervention after the initial training class.
Number of subjects: 308
Study: 6131488

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Halazepam or Oxazepam
Number of subjects: 29
Study: 31764271

Group type: EXPERIMENTAL
Intervention: Cash transfers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Food assistance
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Optimized cash transfer intervention
Number of subjects: 0
Study: 27770561

Group type: EXPERIMENTAL
Intervention: elbasvir (EBR) 50 mg/grazoprevir (GZR) 100 mg with sofosbuvir (SOF) 400 mg for 4 weeks
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: elbasvir (EBR) 50 mg/grazoprevir (GZR) 100 mg with sofosbuvir (SOF) 400 mg for 6 weeks
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: elbasvir (EBR) 50 mg/grazoprevir (GZR) 100 mg with sofosbuvir (SOF) 400 mg for 8 weeks
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: elbasvir (EBR) 50 mg/grazoprevir (GZR) 100 mg with sofosbuvir (SOF) 400 mg for 12 weeks
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Retreatment with EBR/GZR+SOF and ribavirin for 12 weeks
Number of subjects: 31
Study: 27376706

Group type: EXPERIMENTAL
Intervention: Sofosbuvir 400 mg once daily plus ribavirin 1,000 mg/day for 16 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sofosbuvir 400 mg once daily plus ribavirin 1,000 mg/day for 24 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sofosbuvir 400 mg once daily plus ribavirin 1,200 mg/day for 16 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sofosbuvir 400 mg once daily plus ribavirin 1,200 mg/day for 24 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sofosbuvir plus ribavirin (both dosages)
Number of subjects: 0
Study: 24210653

Group type: EXPERIMENTAL
Intervention: E-cap (cap-assisted gastroscope)
Number of subjects: 139

Group type: COMPARATOR
Intervention: C-cap (cap-assisted colonoscope)
Number of subjects: 139
Study: 22364892

Group type: EXPERIMENTAL
Intervention: onabotulinumtoxinA (botulinum toxin injection to the glabellar region)
Number of subjects: 30

Group type: COMPARATOR
Intervention: placebo (saline injection)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: onabotulinumtoxinA
Number of subjects: 30
Study: 19581770

Group type: EXPERIMENTAL
Intervention: Clevudine therapy
Number of subjects: 271
Study: 17975845

Group type: EXPERIMENTAL
Intervention: Extracorporeal albumin dialysis (ECAD) + standard medical therapy (SMT)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Standard medical therapy (SMT) alone
Number of subjects: 70
Study: 16358599

Group type: EXPERIMENTAL
Intervention: 4% lidocaine
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: 2% lidocaine
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: 1% lidocaine
Number of subjects: 43

Group type: COMPARATOR
Intervention: Normal saline solution
Number of subjects: 43

Group type: COMPARATOR
Intervention: No topical anesthetic
Number of subjects: 43
Study: 12473473

Group type: EXPERIMENTAL
Intervention: Intranasal mupirocin ointment for 5 days
Number of subjects: 484

Group type: EXPERIMENTAL
Intervention: Retreatment with mupirocin
Number of subjects: 484
Study: 10496153

Group type: EXPERIMENTAL
Intervention: Cefpodoxime proxetil suspension (10mg/kg/day)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Cefaclor suspension (45mg/kg/day)
Number of subjects: 57
Study: 7650209

Group type: EXPERIMENTAL
Intervention: Presence of human herpesvirus 6 (HHV‐6) variant A
Number of subjects: 0

Group type: COMPARATOR
Intervention: Presence of human herpesvirus 7 (HHV‐7)
Number of subjects: 0
Study: 2696009

Group type: EXPERIMENTAL
Intervention: Dexamethasone (4 mg before or after the operation or 8 mg after the operation)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 6-methylprednisolone (16 mg at the end of the operation)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Nothing (control group)
Number of subjects: 100
Study: 326596

Group type: EXPERIMENTAL
Intervention: Mazindol therapy
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: Mazindol plus behavioural modification
Number of subjects: 245

Group type: COMPARATOR
Intervention: Placebo therapy
Number of subjects: 245
Study: 29654540

Group type: EXPERIMENTAL
Intervention: 12-week mindfulness intervention
Number of subjects: 145
Study: 28885054

Group type: EXPERIMENTAL
Intervention: Zephyr endobronchial valve (EBV) treatment
Number of subjects: 97

Group type: COMPARATOR
Intervention: Standard of care (SoC)
Number of subjects: 97
Study: 25204361

Group type: EXPERIMENTAL
Intervention: Topical minoxidil foam 5% (MTF)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 23144466

Group type: EXPERIMENTAL
Intervention: DHEA (LiveWell, 25 mg three times a day)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 21700161

Group type: EXPERIMENTAL
Intervention: Stainless steel piercings
Number of subjects: 85

Group type: COMPARATOR
Intervention: Polytetrafluoroethylene piercings
Number of subjects: 85

Group type: COMPARATOR
Intervention: Polypropylene piercings
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Overall findings
Number of subjects: 85
Study: 19394002

Group type: EXPERIMENTAL
Intervention: Acupuncture (according to traditional Chinese medicine principles)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo acupuncture
Number of subjects: 57
Study: 17062435

Group type: EXPERIMENTAL
Intervention: High-dose omega-3 (4.55 g omega-3/day)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Low-dose omega-3 (1.95 g omega-3/day)
Number of subjects: 24
Study: 14550444

Group type: EXPERIMENTAL
Intervention: 17-gauge coaxial TruGuide needle
Number of subjects: 102

Group type: COMPARATOR
Intervention: Conventional transperineal technique
Number of subjects: 102
Study: 10965421

Group type: EXPERIMENTAL
Intervention: Tramadol hydrochloride injection (Limadol), 100 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Commercially available reference product, 100 mg
Number of subjects: 12
Study: 8779143

Group type: EXPERIMENTAL
Intervention: Salbutamol (1200 micrograms) - Salamol
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Salbutamol (1200 micrograms) - Salbulin
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Salbutamol (1200 micrograms) - Ventolin
Number of subjects: 10

Group type: COMPARATOR
Intervention: Salbulin vs Ventolin
Number of subjects: 10

Group type: COMPARATOR
Intervention: Salamol vs Ventolin
Number of subjects: 10
Study: 1352908

Group type: EXPERIMENTAL
Intervention: Ebrotidine (800 mg single oral dose)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ebrotidine (3 days treatment)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (3 days treatment)
Number of subjects: 12
Study: 6241188

Group type: EXPERIMENTAL
Intervention: 13-cis-retinoic acid (0.05 mg/kg)
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: 13-cis-retinoic acid (0.1 mg/kg)
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: 13-cis-retinoic acid (0.2 mg/kg)
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: 13-cis-retinoic acid (all doses)
Number of subjects: 191
Study: 30874474

Group type: EXPERIMENTAL
Intervention: injectable sponge
Number of subjects: 360

Group type: COMPARATOR
Intervention: plain gauze
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: z‐folded gauze
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: s‐rolled gauze
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: all arms
Number of subjects: 360
Study: 29202566

Group type: EXPERIMENTAL
Intervention: Spray-Sol group (18 patients) with HA nebulized using a new nasal device named Spray-Sol
Number of subjects: 33

Group type: COMPARATOR
Intervention: Spray group (15 patients) with HA nebulized with a common spray
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Spray-Sol group (18 patients)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 33
Study: 25914337

Group type: EXPERIMENTAL
Intervention: Intravesical onabotulinumtoxinA (BoNT‐A) 100 U
Number of subjects: 60

Group type: COMPARATOR
Intervention: Normal saline (N/S)
Number of subjects: 60
Study: 25027139

Group type: EXPERIMENTAL
Intervention: Telecare management (n=124) for 12 months with automated symptom monitoring and algorithm-guided stepped care approach to optimizing analgesics
Number of subjects: 250

Group type: COMPARATOR
Intervention: Usual care (n=126)
Number of subjects: 250